Latest Breaking News On - Emerson perin - Page 3 : comparemela.com

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure NEW YORK, Dec. 14, 2020 Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results from the landmark DREAM-HF Phase 3 randomized controlled trial of its allogeneic cell therapy rexlemestrocel-L (REVASCOR ®) in 537 patients with advanced chronic heart failure 1. Over a mean 30 months of follow-up, patients with advanced chronic heart failure who received a single endomyocardial treatment with rexlemestrocel-L on top of maximal therapies had 60% reduction in incidence of heart attacks or strokes and 60% reduction in death from cardiac causes when treated at an earlier stage in the progressive disease process. Despite significant reduction in the pre-specified endpoint of car

United statesBaylor college of medicineSilviu itescuKristen bothwellPaul hughesEmerson perinSchond greenwayFred grossmanTexas heart instituteYork heart associationDrug administrationAustralian securities exchangeMesoblast limited nasdaqCorporate communications investorsClinical researchMesoblast limited